Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic MiceNasdaqCAMBRIDGE, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results… Continue reading
Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic MiceNasdaqCAMBRIDGE, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results… Continue reading
Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic MiceNasdaqCAMBRIDGE, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results… Continue reading
Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic MiceGlobeNewswire (press release)CAMBRIDGE, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, … Continue reading
Creative Medical Technology Holdings Announces Commercialization of patented Stem Cell Procedure for Erectile …PR Newswire (press release)An independent medical safety monitor was also appointed to review the patient data for safety and feasibility o… Continue reading
|
FDA Approves Gilead Cancer Gene Therapy
HuffPost (Reuters) – U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc’s (GILD.O) Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. |
|
CRISPR Gene Editing Aims to Improve ‘Orphan Crops’
agprofessional.com Nigel and other researchers are working to stay ahead of cassava brown streak using a new technology: Clustered Regularly Interspaced Short Palindromic Repeat, or CRISPR. CRISPR allows geneticists to identify a specific genetic sequence within an … |
Medical News Today |
‘Synthetic gene circuit’ may improve effectiveness of cancer immunotherapy
Medical News Today Researchers from the Massachusetts Institute of Technology (MIT) in Cambridge suggest that their artificial DNA-encoded circuits may help to overcome some of the problems that have dogged the translation of cancer immunotherapy from the laboratory to … Gene circuit switches on inside cancer cells, triggers immune attackMedical Xpress |